NCT02505451View on ClinicalTrials.gov

Myocardial Regional Function by Dobutamine Stress Echocardiography in the Metabolic Syndrome and Type 2 Diabetes

NACompletedINTERVENTIONAL

Enrollment

125

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2019

Conditions

Diabetes-related Complications

Interventions

DRUG

dobutamine

In each participant, dobutamine will be administered via intravenous infusion in doses of 10, 20, 30 and 40 lg/kg/min during 3-min stages and 2D strain echocardiography will be performed at each stage.

Trial Locations (1)

84000

Hospital Henri Duffaut, Avignon

All Listed Sponsors

lead

University of Avignon

OTHER

NCT02505451 - Myocardial Regional Function by Dobutamine Stress Echocardiography in the Metabolic Syndrome and Type 2 Diabetes | Biotech Hunter | Biotech Hunter